Login to Your Account

Financings NEWS

After quietly incubating for a year, Magenta Therapeutics burst onto the cell therapy scene with a $48.5 million A round to advance its goal of transforming stem cell transplantation for patients with autoimmune diseases, genetic blood disorders and cancer.

HONG KONG – Newly capitalized, thanks to an IPO of its contract drug manufacturing arm that surged on its first day of trading, South Korea's Samsung Group is now looking to take a larger slice of the global biotechnology market pie.

Messenger RNA drug developer Curevac AG added $29.5 million in new funds to its coffers from German investors looking to support the home team in a hot field defined by sizable early investments.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: